OBJECTIVES: To assess the ability of C-reactive protein (CRP) to predict long-term outcomes in a chest pain population. DESIGN AND METHODS: CRP was measured at presentation in 446 emergency department patients with acute coronary syndromes. All-cause mortality and hospital discharges for acute myocardial infarction (AMI) and congestive heart failure (CHF) were obtained for up to 8 years following the event. RESULTS: Kaplan-Meier analyses indicated that patients with CRP concentrations above the American Heart Association scientific statement cut-off had a higher rate for death and CHF admissions. After adjusting for troponin concentrations, in a Cox proportional hazard model, only CRP concentrations indicative of an acute phase response (i.e., >7.44 mg/L) were associated with a significant risk for death after 5 years and CHF readmission after 2 years. CONCLUSIONS: Patients presenting early with chest pain with elevated CRP concentrations have a greater long-term risk for death and heart failure.
OBJECTIVES: To assess the ability of C-reactive protein (CRP) to predict long-term outcomes in a chest pain population. DESIGN AND METHODS: CRP was measured at presentation in 446 emergency department patients with acute coronary syndromes. All-cause mortality and hospital discharges for acute myocardial infarction (AMI) and congestive heart failure (CHF) were obtained for up to 8 years following the event. RESULTS: Kaplan-Meier analyses indicated that patients with CRP concentrations above the American Heart Association scientific statement cut-off had a higher rate for death and CHF admissions. After adjusting for troponin concentrations, in a Cox proportional hazard model, only CRP concentrations indicative of an acute phase response (i.e., >7.44 mg/L) were associated with a significant risk for death after 5 years and CHF readmission after 2 years. CONCLUSIONS:Patients presenting early with chest pain with elevated CRP concentrations have a greater long-term risk for death and heart failure.
Authors: Peter A Kavsak; Dennis T Ko; Alice M Newman; Viliam Lustig; Glenn E Palomaki; Andrew R MacRae; Allan S Jaffe Journal: Clin Biochem Date: 2007-12-27 Impact factor: 3.281
Authors: Peter A Kavsak; Xuesong Wang; Matthew Henderson; Dennis T Ko; Andrew R MacRae; Allan S Jaffe Journal: Clin Biochem Date: 2009-03-25 Impact factor: 3.281
Authors: Ricardo León de la Fuente; Patrycja A Naesgaard; Stein Tore Nilsen; Leik Woie; Torbjoern Aarsland; Patricio Gallo; Heidi Grundt; Harry Staines; Dennis W T Nilsen Journal: BMC Cardiovasc Disord Date: 2011-09-29 Impact factor: 2.298
Authors: Trygve Brügger-Andersen; Volker Pönitz; Harry Staines; David Pritchard; Heidi Grundt; Dennis W T Nilsen Journal: BMC Cardiovasc Disord Date: 2008-11-25 Impact factor: 2.298